| Description | BM635 is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv). |
| In vivo | BM635 has potent MIC (0.12 μM), Tox50:MIC ratio of >100, and good microsomal stability in mice (1.4 mL/min/g). When tested in an acute murine infection model at multiple doses, BM635 exhibits potent anti-tubercular activity (ED99: 49 mg/Kg; IC95%: 43–54 mg/Kg) [1]. The half-life in vivo of BM635 is 1h, allowing a reasonable maximum concentration (Cmax: 1.62 μM) and a moderate bioavailability (46%) [2]. |
| Target activity | M. tuberculosis (strain H37Rv):（MIC50） 0.12 μM |
| molecular weight | 392.51 |
| Molecular formula | C25H29FN2O |
| CAS | 1493762-74-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 31 mg/mL (78.98 mM), Sonication and heating are recommended. |
| References | 1. Poce G, et al. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. PLoS One. 2013;8(2):e56980. 2. Poce G, et al. Pharmaceutical salt of BM635 with improved bioavailability. Eur J Pharm Sci. 2017 Mar 1;99:17-23. |